Aurinia Pharmaceuticals to Present at Three Upcoming Virtual Investor Conferences

VICTORIA, British Columbia-- Aurinia Pharmaceuticals Inc today announced that members of the senior management team will participate in fireside chats during the following upcoming virtual investor conferences:

  • H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 14, 2020 at 10:30 a.m. EDT.
  • Cantor Virtual Global Healthcare Conference on September 16, 2020 at 4:00 p.m. EDT.
  • Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 23, 2020 at 1:40 p.m. ET.

In order to participate in the audio webcast, interested parties can register and access the live webcast under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.

ABOUT AURINIA

Aurinia Pharmaceuticals is a late-stage clinical biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company is currently seeking FDA approval of voclosporin for the potential treatment of lupus nephritis and evaluating voclosporin ophthalmic solution (VOS) in a Phase 2/3 study for the treatment of dry eye syndrome. The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub in Rockville, Maryland, and focuses its development efforts globally.

Investor & Corporate Contact:
Glenn Schulman, PharmD, MPH
SVP, Corporate Communications & IR
gschulman@auriniapharma.com

Source: Aurinia Pharmaceuticals Inc

Related Posts

Subscribe Our Newsletter